Singm News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Singm. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Singm Today - Breaking & Trending Today

Pale Fire Capital SE Acquires New Position in NGM Biopharmaceuticals, Inc. (NASDAQ:NGM)

Pale Fire Capital SE bought a new stake in NGM Biopharmaceuticals, Inc. (NASDAQ:NGM – Free Report) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 33,800 shares of the company’s stock, valued at approximately $36,000. Several other hedge funds and […] ....

Blackrock Inc , Biopharmaceuticals Inc , Vanguard Group Inc , Exchange Commission , Acadian Asset Management , Pale Fire Capital , Free Report , Asset Management , State Street Corp , Street Corp , Visit Holdingschannel , Ngm Biopharmaceuticals , Nasdaq Ngm , Sec Filings , Hedge Fund Holdings , Institutional Investor Holdings ,

NGM Biopharmaceuticals (NASDAQ:NGM) vs. NextCure (NASDAQ:NXTC) Head-To-Head Review

NGM Biopharmaceuticals (NASDAQ:NGM – Get Free Report) and NextCure (NASDAQ:NXTC – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, dividends, institutional ownership, valuation, risk, analyst recommendations and earnings. Earnings & Valuation This table compares NGM Biopharmaceuticals […] ....

United States , South San Francisco , Yale University , Merck Sharp Dohme Corp , Nextcure Inc , Biopharmaceuticals Inc , Get Free Report , Merck Sharp , Dohme Corp , Ngm Biopharmaceuticals , Nasdaq Ngm , Stock Comparison , Stock Analysis ,

NGM Biopharmaceuticals (NASDAQ:NGM) Price Target Cut to $3.50 by Analysts at B. Riley

NGM Biopharmaceuticals (NASDAQ:NGM – Free Report) had its target price reduced by B. Riley from $7.00 to $3.50 in a research note issued to investors on Wednesday morning, Benzinga reports. They currently have a buy rating on the stock. NGM Biopharmaceuticals Price Performance NASDAQ:NGM opened at $0.76 on Wednesday. The firm has a market cap […] ....

Biopharmaceuticals Company Profile , Blackrock Inc , Acadian Asset Management , Vanguard Group Inc , Biopharmaceuticals Inc , Free Report , Get Free Report , Asset Management , Ngm Biopharmaceuticals , Nasdaq Ngm , Lower Price Target , B Riley ,

Short Interest in NGM Biopharmaceuticals, Inc. (NASDAQ:NGM) Decreases By 17.9%

NGM Biopharmaceuticals, Inc. (NASDAQ:NGM – Get Free Report) saw a large decrease in short interest in the month of August. As of August 31st, there was short interest totalling 2,520,000 shares, a decrease of 17.9% from the August 15th total of 3,070,000 shares. Approximately 5.7% of the shares of the stock are sold short. Based […] ....

Ngm Biopharmaceuticals Inc , Blackrock Inc , Acadian Asset Management , Biopharmaceuticals Inc , Vanguard Group Inc , Get Free Report , Asset Management , Ngm Biopharmaceuticals , Nasdaq Ngm ,